Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | ME2 | P23368 | 1/20 | 0.46 |
| ▸ | ME1 | P48163 | 1/20 | 0.46 |
| ▸ | ME3 | Q16798 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408011 | 0.83 | CASP6 (0.42) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL31149178 | 0.81 | CYP1A2 (0.62) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL245378 | 0.81 | CYP1A2 (0.62) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL4980294 | 0.81 | KMT2A (0.56) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL5179019 | 0.81 | MEN1 (0.56) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL3926157 | 0.80 | MEN1 (0.48) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL5375009 | 0.80 | MEN1 (0.60) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL28060760 | 0.79 | MEN1 (0.58) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL2791213 | 0.79 | CYP1A2 (0.58) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 | |
| SCHEMBL8460754 | 0.78 | MEN1 (0.58) | HPGDHSD17B10CYP1A2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107965-A1 | SALT AND SOLID FORMS OF 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE (DOM), 2,5-DIMETHOXY-4-IODOAMPHETAMINE (DOI), 2,5-DIMETHOXY-4-BROMOAMPHETAMINE (DOB), AND 2,5-DIMETHOXY-4-CHLOROAMPHETAMINE (DOC) | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023227867-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Cerevance, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3236970-B1 | NEW METAL COMPLEXES OF NOCARDAMINE AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | CHEVION MORDECHAI (IL) | 2020-12-16 | — | — | EP | disclosed |
| EP-2490670-B1 | COMPOSITION FOR INHALATION | INNOVATA LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-10188616-B2 | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same | TEIKOKU PHARMA USA, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180289640-A1 | Topical Sphingosine-1-Phosphate Receptor Agonist Formulations and Methods of Using the Same | TEIKOKU PHARMA USA, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3160965-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| WO-2007076875-A2 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | AARHUS UNIVERSITET (DK) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006125596-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006108572-A2 | NOVEL CRYSTALLINE PHARMACEUTICAL PRODUCT | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006087140-A1 | NOVELL PROCESSES FOR THE PREPARATION OF A BENZOFURAN | ARPIDA AG (CH) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006067073-A1 | COATING COMPOSITIONS FOR MARKING SUBSTRATES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| EP-1268581-B1 | STABLE INITIATOR SYSTEM | JOHNSON & JOHNSON VISION CARE (US) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | HPGD 3517/4885HSD17B10 1238/4885CYP1A2 3167/4885 |
| US-20180289640-A1 | Topical Sphingosine-1-Phosphate Receptor Agonist Formulations and Methods of Using the Same | S1PR1, S1PR4, S1PR2 | HPGD 3592/4885HSD17B10 3472/4885CYP1A2 4064/4885 |
| US-10188616-B2 | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same | S1PR1, S1PR4, S1PR2 | HPGD 3592/4885HSD17B10 3472/4885CYP1A2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.